HomeAbout
About
Acceptance rate:
21%
Time to first decision with review:
45 days*
Acceptance to publication:
27 days*
2023 total content views:
28516
*median number of days
Aims and scope
BMJ Oncology is a new BMJ journal that aims to optimise cancer patient care and improve outcomes. An open access, online format supports the global reach and impact of BMJ Oncology content.
The journal invites oncology experts to submit high-quality original research and review papers. Publishing consideration will be extended to papers that provide sound science across the broad spectrum of cancer research, investigation, treatment and practice.
BMJ Oncology aims to improve cancer outcomes by:
- Publishing a broad range of peer-reviewed articles that provide significant clinical, scientific and educational value
- Reaching a wide international audience through BMJ’s global recognition and clinical following
- Facilitating a close interaction between basic, translational and clinical sciences through publication and by fostering interdisciplinary research
- Provoking scientific debate and discussion
- Encouraging researchers, clinicians, patients and the public to engage with the journal content and contribute through social media and multimedia
Ownership
BMJ Oncology is wholly owned by BMJ.
Journal information
Publication Model
Open access
Frequency
Continuous online publication
Launch date
2022
Indexed by
Google Scholar
Peer Review Model
Single anonymised; the names of reviewers are hidden from the author
Online ISSN
2752-7948
Journal Statistics 2023
Speed
Time to first decision without review: 2 days (median)
Time to first decision with review: 45 days (median)
Acceptance to publication: 27 days (median)
Reach
2023 total content views: 28516
2023 total Altmetric mentions: 7295
Contact information
For all contact information please refer to the contact us page.
For authors
Please refer to the Instructions for authors.
Advertising
BMJ sales
Display advertising sales – worldwide except USA and Canada
Sophie Fitzsimmons (Sales Executive)
sfitzsimmons@bmj.com
Online advertising sales – worldwide except USA and Canada
Marc Clifford (Sales Manager)
mclifford@bmj.com
Display & online advertising sales – USA and Canada
Jim Cunningham
jcunningham@cunnasso.com
Tel: +1 201 767 4170
Information and rates on how to advertise in BMJ Oncology
Rights and permissions
Please refer to our Permissions guidelines
Affiliations
The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure.
How we get these metrics
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.